NCT06987305View on ClinicalTrials.gov

Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

820

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2028

Study Completion Date

January 1, 2029

Conditions
Stroke, Acute Ischemic
Interventions
DRUG

Intravenous rhTNK-tPA

Patients will received intravenous rhTNK-tPA

DRUG

Intravenous placebo

Patients will received intravenous placebo

PROCEDURE

Endovascular thrombectomy

Patients will received endovascular thrombectomy

All Listed Sponsors
collaborator

China Shijiazhuang Pharmaceutical Company RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD

UNKNOWN

lead

Xinqiao Hospital of Chongqing

OTHER